GMP IPO Watch
ABH Healthcare IPO 2026 – Final Day Update
ABH Healthcare Limited's NSE SME IPO has reached its final bidding day today, August 27, 2026.
The IPO has a price band of ₹96 to ₹102 per share and an issue size of up to ₹34.98 crore. It consists entirely of fresh shares, meaning there is no Offer for Sale component.
ABH Healthcare IPO Details
| Particular | Details |
|---|---|
| IPO Type | NSE SME IPO |
| Issue Size | ₹34.98 Crore |
| Fresh Issue | ₹34.98 Crore |
| Offer for Sale | Nil |
| Shares Offered | 34,29,600 |
| Price Band | ₹96 – ₹102 |
| Face Value | ₹10 |
| Minimum Bid | 2,400 Shares |
| Lot Multiple | 1,200 Shares |
| Minimum Investment | ₹2,44,800 |
| IPO Open Date | August 24, 2026 |
| IPO Close Date | August 27, 2026 |
| Listing Platform | NSE SME |
At the upper price of ₹102, the minimum application of 2,400 shares requires ₹2,44,800.
ABH Healthcare IPO Subscription
The IPO entered its final day after overall subscription reached approximately 0.99x through August 26.
The standout category has been institutional investors. The QIB portion was subscribed 8.37 times, while retail demand was approaching full subscription.
| Category | Subscription Through Aug. 26 |
|---|---|
| QIB | 8.37x |
| NII | 0.17x |
| Retail | 0.93x |
| Overall | 0.99x |
The final-day figures can change considerably before bidding closes, so the eventual subscription numbers may be higher.
ABH Healthcare IPO GMP Today
Unlike several other IPOs currently attracting high grey-market premiums, ABH Healthcare's GMP remains subdued.
The latest available update on August 27, 2026 shows a GMP of ₹0.
| GMP Particular | Latest |
|---|---|
| Upper Issue Price | ₹102 |
| GMP | ₹0 |
| Indicative Price | ₹102 |
| Indicative Gain | 0% |
| Sentiment | Neutral |
The tracker also shows GMP remaining at ₹0 across recent sessions.
GMP is unofficial and should not be treated as a guaranteed indication of the eventual listing price.
What Does ABH Healthcare Do?
ABH Healthcare operates a 150-bed multi-specialty tertiary-care hospital under the Anil Baghi Hospital brand in Ferozepur, Punjab.
The hospital provides around 25 medical specialties, including cardiac sciences, neurology, gastroenterology, orthopaedics, minimally invasive surgery and critical care.
The company's business model is primarily:
hospital infrastructure → specialist doctors → patient treatment → healthcare revenue.
Unlike a hospital chain operating across multiple cities, ABH Healthcare currently has significant dependence on its Ferozepur facility.
FY2026 Revenue Reached ₹52.59 Crore
ABH Healthcare has recorded improving financial performance over the last three reported years.
| Financial Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | ₹41.39 Cr | ₹49.32 Cr | ₹52.59 Cr |
| EBITDA | ₹6.89 Cr | ₹13.20 Cr | ₹14.72 Cr |
| PAT | ₹1.66 Cr | ₹5.35 Cr | ₹5.64 Cr |
| Net Worth | ₹6.30 Cr | ₹11.60 Cr | ₹17.27 Cr |
| Total Assets | ₹51.35 Cr | ₹63.90 Cr | ₹85.27 Cr |
| Borrowings | ₹30.59 Cr | ₹33.78 Cr | ₹45.75 Cr |
Revenue increased by around 6.6% in FY2026, while PAT increased approximately 5.4%.
The longer-term trend is stronger: PAT increased from ₹1.66 crore in FY2024 to ₹5.64 crore in FY2026.
ABH Healthcare IPO Valuation
At the upper price band, the company's latest reported valuation and profitability indicators are:
| KPI | FY2026 / IPO |
|---|---|
| ROE | 39.07% |
| ROCE | 19.09% |
| EBITDA Margin | 28.03% |
| PAT Margin | 10.74% |
| Debt / Equity | 3.20 |
| EPS – Pre Issue | ₹7.05 |
| EPS – Post Issue | ₹4.93 |
| NAV | ₹21.58 |
| Pre-Issue P/E | 14.47x |
| Post-Issue P/E | 20.69x |
| Post-Issue Market Cap | ₹116.58 Cr |
The post-issue P/E of around 20.69x is particularly relevant because fresh shares increase the equity base after the IPO.
Debt Is the Main Financial Issue
One of the most important points in ABH Healthcare's financial profile is its borrowings.
Debt increased from:
₹30.59 crore in FY2024 → ₹33.78 crore in FY2025 → ₹45.75 crore in FY2026.
The FY2026 debt-to-equity ratio stood at approximately 3.20, which makes deleveraging an important part of the IPO story.
This is also why the company intends to use a substantial portion of IPO proceeds to repay borrowings.
₹17 Crore Will Be Used for Debt Repayment
ABH Healthcare plans to use ₹17 crore from the IPO proceeds toward repayment or prepayment of certain borrowings.
Another ₹5 crore is earmarked for working-capital requirements.
| Use of Proceeds | Amount |
|---|---|
| Debt Repayment / Prepayment | ₹17.00 Cr |
| Working Capital | ₹5.00 Cr |
| Inorganic Growth & General Corporate Purposes | Balance |
| Total IPO | ₹34.98 Cr |
Debt repayment represents nearly 49% of the overall issue size.
The potential impact is straightforward:
IPO funds → lower borrowings → lower finance costs → stronger balance sheet → improved financial flexibility.
IPO Is 100% Fresh Issue
ABH Healthcare's issue structure is another important point.
| Component | Amount | Share |
|---|---|---|
| Fresh Issue | ₹34.98 Cr | 100% |
| Offer for Sale | Nil | 0% |
| Total Issue | ₹34.98 Cr | 100% |
There is no promoter or existing shareholder OFS.
Therefore, the capital raised through the IPO goes to the company for the stated objects rather than to selling shareholders.
Promoter holding is expected to decline from 100% before the issue to approximately 69.99% after the IPO because of the new shares being issued.
Single-Hospital Dependence Is the Biggest Business Risk
ABH Healthcare currently generates significant revenue from a single hospital located in Ferozepur, Punjab.
This creates concentration risk.
Any major disruption involving the facility could affect a large portion of the company's operations.
Potential issues include:
regulatory problems + infrastructure disruption + loss of key doctors + local competition + lower patient volumes.
Another important point is that ABH Healthcare does not own the hospital premises; the facility operates on a leasehold basis.
Tier-3 Healthcare Is Also an Opportunity
The same geographic concentration creates a potential opportunity.
Patients in smaller cities often need to travel to larger cities for specialised healthcare.
A tertiary-care hospital capable of providing cardiac, neurological, orthopaedic, gastroenterological and critical-care services locally can potentially capture demand that would otherwise move to larger healthcare centres.
The opportunity can therefore be viewed as:
regional population + specialist healthcare + local accessibility → higher patient volumes and hospital utilisation.
Profit Margins Have Improved
ABH Healthcare reported an FY2026 EBITDA margin of 28.03% and PAT margin of 10.74%.
These margins are important because hospital businesses have substantial fixed costs.
Once infrastructure, doctors, equipment and staff are in place, higher occupancy can potentially improve operating leverage.
Investors should therefore closely track:
bed occupancy + patient volumes + revenue per occupied bed + EBITDA margin.
These metrics can provide a clearer indication of operational performance than revenue alone.
Key Strengths
ABH Healthcare's main positives include its established 150-bed multi-specialty hospital, broad range of medical specialties and significant improvement in profitability between FY2024 and FY2026.
PAT increased from ₹1.66 crore to ₹5.64 crore during this period, while FY2026 EBITDA reached ₹14.72 crore.
Another positive is the 100% fresh-issue structure, particularly because ₹17 crore is specifically earmarked for debt repayment.
Major Risks
The main risks investors should monitor include:
- Dependence on a single hospital
- High debt-to-equity ratio
- Rising borrowings
- Dependence on specialist doctors and key healthcare professionals
- Regulatory and legal risks associated with healthcare
- Hospital operating on leased premises
- Medical-equipment and technology requirements
- Patient-volume fluctuations
- Competition from other hospitals
- SME-platform liquidity and volatility
The latest ₹0 GMP also shows that grey-market sentiment is currently neutral despite strong QIB subscription.
What Investors Should Track After Listing
| Metric | Why It Matters |
|---|---|
| Bed Occupancy | Hospital utilisation |
| Patient Volumes | Demand |
| Revenue Growth | Business expansion |
| EBITDA Margin | Operating efficiency |
| PAT Margin | Earnings quality |
| Borrowings | IPO debt repayment |
| Debt / Equity | Balance-sheet improvement |
| Finance Cost | Deleveraging benefit |
| Operating Cash Flow | Earnings quality |
| New Specialties | Organic expansion |
| Acquisitions | Geographic diversification |
| New Hospitals | Concentration reduction |
Final View on ABH Healthcare IPO
The ABH Healthcare IPO closes today, August 27, 2026. The NSE SME issue is priced at ₹96–₹102 and raises up to ₹34.98 crore entirely through fresh shares.
Through August 26, the IPO stood at approximately 0.99x overall subscription, with the QIB category strongly subscribed at 8.37x and retail at 0.93x.
Meanwhile, the latest August 27 GMP is ₹0, indicating neutral unofficial grey-market sentiment.
Fundamentally, ABH Healthcare reported ₹52.59 crore FY2026 revenue, ₹14.72 crore EBITDA and ₹5.64 crore PAT. The biggest financial concern is leverage, with borrowings at ₹45.75 crore and debt/equity at 3.20.
